Recipharm, Medspray & Resyca Enter Exclusive License Agreement to Develop Nasally Delivered Drug Products Using Proprietary Soft Mist Technology
Recipharm recently announced an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination drug products. This collaboration extends the successful partnership between Recipharm and Medspray, which resulted in the joint venture, Resyca; a company which is developing soft mist inhalers utilizing Medspray’s nozzle technology to achieve high lung doses and less degradation of biological active pharmaceutical ingredients.
Under the terms of the agreement, Resyca gains exclusive rights to Medspray’s proprietary spray nozzle technology for use in nasal devices and combination drug products. This collaboration enables Resyca to provide all aspects of turnkey solutions for both oral and nasal inhalation, leveraging soft mist technology.
Han van Egmond, CEO at Medspray, said “Extending this agreement involves combining our cutting-edge nasal technology with Resyca’s product development capabilities. This collaboration with Resyca will enable us to bring innovative solutions to the market that will redefine the landscape of nasal drug delivery.”
It is anticipated that the enhanced collaboration will result in breakthroughs in the nasal delivery of fragile biological formulations, such as mRNA vaccines for pandemic applications.
“We are thrilled to enter into this extended strategic partnership with Medspray,” said Remko Beimers, CEO at Resyca. “This move aligns perfectly with our mission to pioneer advancements in aerosol drug delivery systems. The exclusive licence from Medspray will significantly strengthen our position in the market, allowing us to bring innovative and effective soft mist nasal delivery devices to patients worldwide together with our pharma customers.”
Recipharm, as a key player in the pharmaceutical CDMO industry, recognizes the potential impact of this collaboration on the advancement of nasal drug delivery. “We are proud to be associated with Medspray and Resyca in this landmark licensing agreement,” said Chris Hirst, President, Advanced Delivery Systems at Recipharm. “As a CDMO committed to driving innovation, we look forward to supporting both companies in bringing their pioneering soft mist nasal delivery devices to the market to improve patient experience and expand what is possible via the nasal delivery route.”
Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals and biologics in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com.
Medspray is a privately owned company in Enschede, the Netherlands. With its 40 employees Medspray focuses on the development and manufacturing of micro spray nozzles which are able to deliver soft mists. Medspray’s slogan is: `tiny technology for a sustainable future’. Medspray aims to contribute to a sustainable world by developing innovative spray nozzles for user-friendly health and physical care products. By making propellants redundant and increasing the user-friendliness for various purposes, especially where a slow-moving soft spray is required. Thanks to the high-tech nozzle chips, sprays can be tailored to suit any application, from inhalable aerosol clouds, to gentle nasal sprays, to cosmetic or fragrance sprays that do not feel wet on your skin. For more information, visit www.medspray.com.
About Resyca Resyca was founded in 2020 and is a joint venture between Recipharm and Medspray. Resyca is part of the Recipharm Advanced Delivery Systems business unit. Resyca develops and manufactures pocket size, user friendly soft-mist inhalation devices, based on standard pre-filled syringe and filled on standard filling lines. As a soft mist development center with Recipharm, Resyca offers an end-to-end service for soft-mist inhalation products, ranging from early-stage development to commercial manufacture, including filling, labeling, and packaging. For more information, visit www.resyca.com.
Total Page Views: 505